Alimera, pSivida win FDA nod for Iluvien, finally

Shares of Alimera and pSivida continued to rise in premarket trading on 29 September after jumping in after-hours trading on 26 September when they revealed the FDA had finally granted its approval to Iluvien (fluocinolone acetonide intravitreal implant) as a treatment for diabetic macular edema (DME) in patients previously treated with a course of corticosteroids without a clinically significant rise in intraocular pressure.